Sermorelin
Research OnlyAlso known as: Geref, GRF 1-29, GHRH(1-29)NH2
A GHRH analog that was FDA-approved for pediatric GH deficiency. Now discontinued commercially but established safety and efficacy profile exists.
Research Statistics
Previously FDA-approved GHRH(1-29) analog. Established mechanism as GHRH receptor agonist stimulating pituitary GH release. US and European clinical data; moderate research body with human trials supporting GH secretagogue role. Anchor for FDA-approved but limited-scope peptides.
Research Dossier
Overview
What is Sermorelin and what does the research say?
Mechanism of Action
Sermorelin is the biologically active 1-29 amino acid fragment of endogenous GHRH (Growth Hormone-Releasing Hormone). It stimulates the pituitary gland to release growth hormone through receptor-mediated signaling, preserving natural feedback mechanisms.
How It Works (Simplified)
Sermorelin acts as a “release signal” that tells your pituitary gland to produce growth hormone:
Binds to GHRH receptors on pituitary somatotroph cells, triggering the cAMP/PKA signaling cascade that initiates GH synthesis and release.
Stimulates natural pulsatile GH secretion rather than constant elevation, preserving your body’s feedback systems and circadian rhythm.
Acts on CNS GHRH receptors to promote slow-wave sleep independently of peripheral GH effects, enhancing restorative deep sleep phases.
Scientific Pathways
GHRH-R/cAMP/PKA Pathway (Primary GH Release)
Sermorelin → GHRH-R (GPCR) → Gs protein → Adenylyl Cyclase
↓
ATP → cAMP
↓
PKA activation
↓
GH gene transcription + vesicle exocytosisSecondary Pathway (PLC/IP3/DAG)
GHRH-R activation → PLC → IP3 + DAG → Intracellular Ca²⁺ release
↓
Pre-synthesized GH releaseKey Research: Thorner M et al. (USA, 1996) demonstrated 74% growth acceleration in GH-deficient children in the pivotal Geref International Study. PMID:8772599
Important Limitations
- Requires functional pituitary gland to produce effects
- Short half-life (10-20 minutes) necessitates daily administration
- Effects may diminish in severe pituitary damage or destruction
- Was FDA-approved but discontinued in 2008 for business reasons (not safety concerns)
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
GH release begins within 15-30 minutes of subcutaneous injection. Peak GH typically occurs 30-60 minutes post-injection. Sermorelin produces a physiological pulsatile GH response.
Based on clinical trial data: Daily administration establishes regular GH pulsatility. IGF-1 levels begin to rise. Some patients report improved sleep quality early in treatment.
Clinical studies in GH-deficient children showed growth velocity improvements over 6-12 months. In adult studies, IGF-1 levels approached normal ranges with continued use.
Growth velocity improvements documented in pediatric GHD trials. Body composition changes (increased lean mass, reduced fat) may become apparent with continued use.
Long-term pediatric studies showed sustained growth improvements. Sermorelin was FDA-approved for pediatric GHD before discontinuation in 2008 due to manufacturing (not safety) issues.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Sermorelin product quality
Good Signs (7 indicators)
Warning Signs (5 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Sermorelin with other peptides. Based on published research and mechanistic considerations.
Ipamorelin
SynergisticGHRH+GHRP synergy well-documented in literature. Sermorelin (GHRH) combined with ipamorelin (GHRP) produces greater GH release than either alone through complementary receptor pathways.
GHRP-6
SynergisticClassic synergistic combination used in research. GHRH amplifies GH pulse while GHRP initiates release.
GHRP-2
SynergisticComplementary mechanisms through GHRH and ghrelin receptor pathways produce synergistic GH secretion.
MK-677
SynergisticMK-677 acts on ghrelin receptor while sermorelin acts on GHRH receptor. Complementary pathways may enhance GH release.
Semaglutide
CautionGH secretagogues may affect glucose metabolism. Monitor in diabetic patients.
Tesamorelin
AvoidBoth are GHRH analogs acting on the same receptor (GHRH-R). Combination provides no benefit and may cause receptor desensitization.
CJC-1295
AvoidBoth are GHRH analogs with identical mechanism of action. Use one or the other.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Sermorelin
Sermorelin Calculators
Related Peptides
Follistatin
FST, FS-344, FS-315 +1 more
An endogenous glycoprotein that inhibits myostatin and activin signaling, potentially allowing muscle growth beyond genetic limits. Gene therapy trials for muscular dystrophy show promise, but injectable peptide forms remain unapproved and understudied in humans.
GHRP-2
Growth Hormone Releasing Peptide-2, Pralmorelin, KP-102
A synthetic hexapeptide GH secretagogue with the strongest GH-releasing potency in its class. More potent than GHRP-6 with different side effect profile: less appetite stimulation but greater cortisol and prolactin elevation. Approved in Japan as Pralmorelin for GH deficiency diagnosis. Extensively studied in human pharmacology with robust clinical data.
GHRP-6
Growth Hormone Releasing Peptide-6, SKF-110679, Growth Hormone-Releasing Hexapeptide
A first-generation growth hormone secretagogue that stimulates GH release through the ghrelin receptor. Less selective than newer alternatives with effects on cortisol and prolactin. Historically significant as the peptide that led to ghrelin discovery. Cuban CIGB leads global cytoprotective research. Not approved for any indication.
Human Chorionic Gonadotropin (hCG)
hCG, Choriogonadotropin, Pregnyl +5 more
A glycoprotein hormone FDA-approved for ovulation induction, cryptorchidism, and hypogonadotropic hypogonadism. Functions as an LH receptor agonist with over 50 years of clinical use in reproductive medicine. Gold standard trigger for assisted reproductive technology.
Hexarelin
Examorelin, HEX, Growth Hormone Releasing Hexapeptide +2 more
The most potent synthetic GHRP (Growth Hormone Releasing Peptide), a hexapeptide that strongly stimulates GH release via the ghrelin receptor. Notable for cardioprotective effects independent of GH release. Development discontinued due to rapid desensitization with repeated dosing. Italian research leads global investigation.
HMG
Human Menopausal Gonadotropin, Menotropins, hMG +4 more
A urinary-derived glycoprotein hormone preparation containing both FSH and LH in approximately 1:1 ratio, FDA-approved for female infertility (ovulation induction, ART) and male hypogonadotropic hypogonadism. First used clinically in 1961 by Bruno Lunenfeld, HMG enabled the birth of the first American IVF baby in 1981 and remains a cornerstone of fertility medicine with over 60 years of clinical experience. Highly purified preparations (HP-hMG) demonstrate comparable or slightly superior live birth rates compared to recombinant FSH in IVF.